Free tool
FAERS Monitor: Copiktra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211155 or its brand name (Copiktra, Duvelisib). Reports on generic versions are filed under their own applications.
Reports
853
Serious
488
57% of reports
Hospitalization
268
Death reported
181
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication237
- diarrhoea112
- death111
- off label use106
- fatigue82
- prescribed underdose65
- product use issue58
- nausea50
- pneumonia42
- pyrexia41
- malignant neoplasm progression40
- rash38
- disease progression37
- hospitalisation36
- asthenia33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 7 |
| 2018 | 20 |
| 2019 | 121 |
| 2020 | 158 |
| 2021 | 98 |
| 2022 | 88 |
| 2023 | 68 |
| 2024 | 65 |
| 2025 | 96 |
| 2026 | 113 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prescribed underdoseSignal | 65 | 80.6 | 63.8 | 5,019 |
| product use in unapproved indicationSignal | 237 | 23.6 | 21.2 | 5,163 |
| malignant neoplasm progressionSignal | 40 | 9.6 | 7.1 | 302 |
| disease progressionSignal | 37 | 7.7 | 5.6 | 211 |
| product use issueSignal | 58 | 7.6 | 5.9 | 329 |
| hospitalisationSignal | 36 | 5.8 | 4.2 | 138 |
| diarrhoeaSignal | 112 | 4.3 | 3.6 | 287 |
| pneumoniaSignal | 42 | 3.2 | 2.4 | 62 |
| deathSignal | 111 | 3.2 | 2.7 | 170 |
| off label useSignal | 106 | 3.0 | 2.5 | 144 |
| pyrexiaSignal | 41 | 2.9 | 2.2 | 51 |
| fatigueSignal | 82 | 2.6 | 2.1 | 82 |
| astheniaSignal | 33 | 2.2 | 1.5 | 20 |
| rashSignal | 38 | 2.1 | 1.6 | 23 |
| nausea | 50 | 1.6 | 1.2 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.